OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
SK Hynix’s $28B U.S. IPO Draws Strong Demand as AI Chip Boom Fuels Investor Interest 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Meta Says States Seek $1.4 Trillion in Penalties Over Teen Social Media Addiction Lawsuit 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Zhipu AI Raises HK$31.37 Billion in Discounted Share Sale to Accelerate AI Growth 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
China 618 Smartphone Sales Drop 13% as Higher Prices Hurt Demand, Huawei Gains Market Share 
Shell Raises Q2 Upstream Outlook, Flags Qatar Gas Hit as Shares Rise 
BUENA, N.J., May 07, 2018 -- Teligent, Inc. (NASDAQ:TLGT), a New Jersey-based specialty generic pharmaceutical company, initially announced the Company would hold a conference call at 4:30pm ET on Monday, May 7, 2018 to discuss the 1st quarter 2018 financial results and business update. This call will be rescheduled for 8:30am ET on Tuesday, May 8, 2018.
The Company invites you to listen to the call by dialing (866) 393-8366. International participants should call (409) 350-3154. Participants should ask to join the Teligent, Inc. call.
This call is available via webcast and can be accessed in the Investor Relations Section of Teligent, Inc.'s website at www.teligent.com.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
Contact:
Damian Finio
Teligent, Inc.
(856) 336-9117
www.teligent.com
